Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D, George B, Hertzberg M, Patil S, Spencer A, Fay K, Cannell P, Berkahn L, Doocey R, Spearing R, Moore J. Bryant A, et al. Among authors: fay k. Bone Marrow Transplant. 2014 Jan;49(1):17-23. doi: 10.1038/bmt.2013.142. Epub 2013 Sep 23. Bone Marrow Transplant. 2014. PMID: 24056743
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Gifford G, Wong K, Kerridge I, Stevenson W, Arthur C, Fay K, Greenwood M. Gifford G, et al. Among authors: fay k. Am J Hematol. 2015 May;90(5):E97-100. doi: 10.1002/ajh.23974. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25683457 Free article. No abstract available.
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ. Kumarasinghe G, et al. Among authors: fay k. J Heart Lung Transplant. 2015 Nov;34(11):1406-14. doi: 10.1016/j.healun.2015.05.021. Epub 2015 Jun 11. J Heart Lung Transplant. 2015. PMID: 26279197
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG). Hertzberg M, et al. Among authors: fay k. Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10. Haematologica. 2017. PMID: 28143954 Free PMC article. Clinical Trial.
Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis.
Ma CKK, García-Cadenas I, Fox ML, Ai S, Nivison-Smith I, Milliken ST, Dodds A, Fay K, Ma DDF, Martino R, Sierra J, Moore J. Ma CKK, et al. Among authors: fay k. Bone Marrow Transplant. 2018 Nov;53(11):1478-1482. doi: 10.1038/s41409-018-0215-4. Epub 2018 May 24. Bone Marrow Transplant. 2018. PMID: 29795434 No abstract available.
205 results